Biomarkers useful in liver fibrosis diagnosis
AssigneeIndustrial Technology Research Institute
InventorsTzu-Ling Tseng, Hung-Yi Li, Yen-Peng Li, Angelina Huai-Lo Lee, Yi-Chen Liu, Ping-Fu Cheng, Wei-Ya Lin, Hong-Zen Yeh
Life of this patent
Estimating the term…
Abstract
Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.
Claims20
A method of diagnosing liver fibrosis in a human subject, comprising:
- obtaining a blood sample from a human subject suspected of having liver fibrosis,
- detecting an expression level(s) of one or more of urokinase-type plasminogen activator (uPA), matrix metalloproteinase 9 (MMP9), and β-2-microglobulin (β-2MG) in the blood sample,
- calculating a disease score based on the expression levels;
- and
- determining whether the subject has fibrosis based on the disease score.
A method of diagnosing liver fibrosis in a human subject, comprising:
- obtaining a blood sample from a human subject suspected of having liver fibrosis,
- detecting in the blood sample expression levels of (a) one or more markers selected from the group consisting of urokinase-type plasminogen activator (uPA), matrix metalloproteinase 9 (MMP9), and β-2-microglobulin (β-2MG), and (b) one or more markers selected from the group consisting of glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), and alpha-fetoprotein (AFP),
- calculating a disease score based on the expression levels;
- and
- determining whether the subject has fibrosis based on the disease score.
A kit for diagnosing liver fibrosis, comprising a first antibody specifically binding to urokinase-type plasminogen activator (uPA), a second antibody specifically binding to matrix metalloproteinase 9 (MMP9), and a third antibody specifically binding to β-2-microglobulin (β-2MG).
A kit for diagnosing liver fibrosis, consisting essentially of a first antibody specifically binding to urokinase-type plasminogen activator (uPA), a second antibody specifically binding to matrix metalloproteinase 9 (MMP9), and a third antibody specifically binding to β-2-microglobulin (β-2MG).
A kit for diagnosing liver fibrosis, comprising (a) an antibody specifically binding to urokinase-type plasminogen activator (uPA), an antibody specifically binding to matrix metalloproteinase 9 (MMP9), an antibody specifically binding to β-2-microglobulin (β-2MG), or a combination thereof;
- and (b) an antibody specifically binding to glutamic oxaloacetic transaminase (GOT), an antibody specifically binding to glutamic pyruvic transaminase (GPT), an antibody specifically binding to alpha-fetoprotein (AFP), or a combination thereof.
A kit for diagnosing liver fibrosis, consisting essentially of (a) an antibody specifically binding to urokinase-type plasminogen activator (uPA), an antibody specifically binding to matrix metalloproteinase 9 (MMP9), an antibody specifically binding to β-2-microglobulin (β-2MG), or a combination thereof;
- and (b) an antibody specifically binding to glutamic oxaloacetic transaminase (GOT), an antibody specifically binding to glutamic pyruvic transaminase (GPT), an antibody specifically binding to alpha-fetoprotein (AFP), or a combination thereof.
Dependencies are inferred from the claim text.